Generic Eliquis ( Apixaban )

Order cheap Generic Eliquis (Apixaban) without dr prescription in the United States

In our USA pharmacy, you can buy Eliquis without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Eliquis (apixaban) is an oral, direct, and highly selective inhibitor of coagulation factor Xa. By blocking free and clot‑bound factor Xa, as well as prothrombinase activity, it prevents thrombin generation and thrombus development without requiring antithrombin III for its antithrombotic effect.
Usual adult dose: For nonvalvular atrial fibrillation (NVAF) the standard dose is 5 mg taken orally twice daily; a reduced dose of 2.5 mg twice daily is used when at least two of the following are present: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. For DVT/PE treatment, 10 mg twice daily is given for the first 7 days, then 5 mg twice daily. For extended prevention of recurrent DVT/PE, 2.5 mg twice daily is used. For DVT prophylaxis following hip or knee replacement, 2.5 mg twice daily.
Dosage form: Film‑coated oral tablets (2.5 mg, 5 mg); also available as a tablet for oral suspension and capsule sprinkle for oral suspension (pediatric formulations).
Onset of action: Peak anticoagulant effect is reached 3–4 hours after oral administration.
Duration of action: Approximately 24 hours with twice‑daily dosing (elimination half‑life about 12 hours).
Alcohol consumption in moderation is generally acceptable; however, chronic heavy alcohol use may increase the risk of gastrointestinal bleeding and should be discussed with a healthcare provider.
Most common side effects: bleeding, bruising, nausea, and anemia.
Would you like to try Eliquis without a prescription?

General Information about Eliquis

• INN (International Nonproprietary Name): Apixaban
• Brand names available in the USA: Eliquis® (Bristol‑Myers Squibb Company and Pfizer Inc.). FDA‑approved generic versions are manufactured by Micro Labs Limited, Prinston Pharmaceutical Inc., and other authorized generic manufacturers.
• ATC code: B01AF02
• Dosage forms and strengths: Film‑coated tablets: 2.5 mg (yellow, round, debossed with “893” and “2½”) and 5 mg (pink, oval‑shaped, debossed with “894” and “5”). Pediatric formulations: tablet for oral suspension (0.5 mg) and capsule sprinkle for oral suspension (0.15 mg).
• Manufacturers in USA: Bristol‑Myers Squibb Company (brand); generic manufacturers include Micro Labs Limited, Prinston Pharmaceutical Inc., and others.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) on December 28, 2012 (NDA 202155).
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Apixaban is a potent, oral, reversible, direct, and highly selective active‑site inhibitor of coagulation factor Xa. It binds directly to the active site of factor Xa, blocking both free factor Xa in plasma and factor Xa bound within the prothrombinase complex. Unlike indirect factor Xa inhibitors such as fondaparinux, apixaban does not require antithrombin III for its activity. By inhibiting factor Xa, apixaban attenuates the conversion of prothrombin (factor II) to thrombin (factor IIa), thereby reducing thrombin generation and subsequent fibrin formation. Apixaban has no direct effect on platelet aggregation, but it indirectly inhibits thrombin‑induced platelet aggregation. It is approximately 30,000‑fold more selective for factor Xa than for other human coagulation proteases. Following oral administration, the absolute bioavailability is approximately 50%, peak plasma concentrations occur within 3–4 hours, and plasma protein binding is about 87%. Apixaban is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2, and is eliminated via both renal (~27%) and biliary/fecal routes. The elimination half‑life is approximately 12 hours, supporting a twice‑daily dosing regimen without the need for routine coagulation monitoring.

Indications

• Reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
• Prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
• Treatment of acute DVT and PE.
• Reduction in the risk of recurrent DVT and PE following initial anticoagulant therapy.
• Pediatric use: treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE following initial therapy in patients from birth to less than 18 years of age.

Important Warnings and Precautions

ELIQUIS CARRIES A BOXED WARNING FOR PREMATURE DISCONTINUATION AND SPINAL/EPIDURAL HEMATOMA. Premature discontinuation of any oral anticoagulant, including apixaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events such as stroke. If apixaban must be stopped for a reason other than pathological bleeding or completion of therapy, consider coverage with another anticoagulant. Epidural or spinal hematomas may occur in anticoagulated patients receiving neuraxial anesthesia or undergoing spinal puncture; these hematomas may result in long‑term or permanent paralysis. Risk factors include indwelling epidural catheters, concomitant use of other drugs affecting hemostasis (e.g., NSAIDs, platelet inhibitors, other anticoagulants), a history of traumatic or repeated epidural or spinal punctures, spinal deformity, or spinal surgery. Eliquis can cause serious and potentially fatal bleeding. Promptly evaluate any signs or symptoms of blood loss. An agent to reverse the anti‑factor Xa activity of apixaban (andexanet alfa) is available for life‑threatening or uncontrolled bleeding. Eliquis is not recommended in patients with prosthetic heart valves or in patients with triple‑positive antiphospholipid syndrome due to a potentially increased risk of recurrent thrombotic events.

At‑risk groups

• Elderly: Age ≥80 years is one of the dose‑reduction criteria for NVAF (2.5 mg twice daily if ≥2 criteria met). No dose adjustment is required based solely on age for other indications, but bleeding risk increases with age.
• Pregnancy: Limited available data are insufficient to inform drug‑associated risks. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy testing is recommended for females of reproductive potential prior to initiating therapy.
• Breastfeeding: Apixaban is present in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment.
• Renal impairment: For NVAF patients with serum creatinine ≥1.5 mg/dL plus age ≥80 years or body weight ≤60 kg, use 2.5 mg twice daily. For end‑stage renal disease (ESRD) on hemodialysis, use 5 mg twice daily (or 2.5 mg twice daily if dose‑reduction criteria are met). For DVT/PE treatment, no dose adjustment is needed in renal impairment; however, avoid use in patients with creatinine clearance
• Hepatic impairment: Contraindicated in severe hepatic impairment. Use with caution in mild‑to‑moderate hepatic impairment (Child‑Pugh A or B); no dose adjustment is required but the risk of bleeding is increased. Not recommended in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
• Pediatric: Eliquis is approved for treatment and prevention of recurrent VTE in pediatric patients from birth to
• Low body weight: Body weight ≤60 kg is a dose‑reduction criterion for NVAF; increased apixaban exposure is observed in low‑body‑weight patients.
• Prosthetic heart valves: Not recommended; safety and efficacy have not been established in patients with prosthetic heart valves (mechanical or bioprosthetic).

Driving and alcohol

Eliquis is not known to impair the ability to drive or operate machinery. However, patients should be aware of the signs and symptoms of bleeding (e.g., dizziness, weakness, fatigue) that may affect driving ability. Alcohol consumption in moderation is generally acceptable. Chronic heavy alcohol intake may increase the risk of gastrointestinal bleeding and liver function abnormalities; patients should discuss their alcohol consumption with their healthcare provider.

Dosage Instructions

• Nonvalvular atrial fibrillation (NVAF): The recommended dose is 5 mg orally twice daily. In patients with at least 2 of the following characteristics — age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL — the recommended dose is 2.5 mg twice daily.
• Prophylaxis of DVT following hip or knee replacement surgery: 2.5 mg orally twice daily. The initial dose should be taken 12–24 hours after surgery. For hip replacement, the recommended duration is 35 days; for knee replacement, 12 days.
• Treatment of acute DVT and PE: 10 mg orally twice daily for the first 7 days, followed by 5 mg twice daily. The usual duration of therapy is at least 3–6 months.
• Reduction in risk of recurrent DVT and PE following initial therapy: 2.5 mg orally twice daily after completion of at least 6 months of treatment for DVT or PE.
• Switching to or from Eliquis: When switching from warfarin, discontinue warfarin and start Eliquis when INR is below 2.0. When switching from other anticoagulants (except unfractionated heparin), discontinue the current anticoagulant and start Eliquis at the next scheduled dose. When switching from Eliquis to warfarin, Eliquis may need to be continued for at least 48 hours after the first dose of warfarin.
• Missed dose: Take the missed dose as soon as remembered on the same day and resume twice‑daily administration. Do not double the dose to make up for a missed one.
• Administration: Tablets may be taken with or without food. For patients unable to swallow whole tablets, 5 mg and 2.5 mg tablets may be crushed and suspended in water, 5% dextrose in water (D5W), or apple juice, or mixed with applesauce and administered promptly. Crushed tablets may also be delivered through a nasogastric tube.

Side Effects and Contraindications

Common side effects: Bleeding events including epistaxis (nosebleeds), contusion, hematuria, gingival bleeding, and menorrhagia; nausea; and anemia. Bleeding events were reported in approximately 25–30% of patients in clinical trials, though most events were minor.
Serious adverse reactions: Major bleeding (including gastrointestinal hemorrhage, intracranial hemorrhage, and intraocular hemorrhage), hemorrhagic stroke, fatal bleeding, and spinal/epidural hematoma. Hypersensitivity reactions including anaphylaxis and allergic edema have been reported rarely. Elevated liver transaminases and bilirubin have been observed.
Absolute contraindications: Active pathological bleeding; severe hypersensitivity reaction to apixaban (e.g., anaphylaxis); and severe hepatic impairment.

Drug Interactions

• Combined P‑gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir): For patients receiving 5 mg or 10 mg twice daily, reduce the dose by 50%. For patients already receiving 2.5 mg twice daily, avoid coadministration. Clarithromycin, although a combined P‑gp and strong CYP3A4 inhibitor, does not require dose adjustment.
• Combined P‑gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort): Avoid concomitant use, as these drugs significantly reduce apixaban exposure and may increase the risk of stroke and other thromboembolic events.
• Anticoagulants and antiplatelet agents (e.g., warfarin, heparin, aspirin, clopidogrel, prasugrel, ticagrelor, NSAIDs, fibrinolytics): Coadministration increases the risk of bleeding. Use with caution; dual or triple antithrombotic therapy should be limited to the shortest duration possible.
• SSRIs and SNRIs: These agents may further impair hemostasis and increase bleeding risk.
• Alcohol: Chronic heavy alcohol use may increase gastrointestinal bleeding risk and should be discussed with a healthcare provider.
• Apixaban does not meaningfully alter the pharmacokinetics of digoxin, naproxen, atenolol, or acetylsalicylic acid.

Practical Advice

• Take Eliquis exactly as prescribed, twice daily (typically morning and evening), with or without food. Consistency in timing helps maintain therapeutic anticoagulation levels.
• Do not discontinue Eliquis without consulting your healthcare provider. Stopping prematurely significantly increases the risk of stroke and other thromboembolic events. If therapy must be interrupted, a bridging strategy with another anticoagulant may be necessary.
• If you miss a dose, take it as soon as you remember on the same day. Do not double the next dose. If you are unsure what to do, contact your healthcare provider.
• Inform all healthcare professionals (including dentists) that you are taking Eliquis before any surgery, invasive procedure, or dental work. Eliquis should generally be stopped at least 24–48 hours before elective surgery, depending on bleeding risk and renal function.
• Watch carefully for signs and symptoms of bleeding: unusual bruising, prolonged bleeding from cuts, nosebleeds, bleeding gums, blood in urine or stool (red, pink, or brown urine; red or black/tarry stools), coughing up blood, vomiting material that looks like coffee grounds, heavy menstrual bleeding, or any bleeding that will not stop. Seek immediate medical attention if bleeding is severe or cannot be controlled.
• Watch for symptoms of spinal or epidural blood clot if you are receiving neuraxial anesthesia or spinal puncture: back pain, numbness or muscle weakness (especially in legs and feet), tingling, or loss of bladder or bowel control. These require emergency medical attention.
• Wear a medical identification bracelet or carry an anticoagulant alert card indicating that you are taking a blood thinner.
• Store at room temperature (20–25°C / 68–77°F) in a dry place, out of reach of children. Keep tablets in the original container.
• Routine laboratory monitoring of coagulation parameters (PT, INR, aPTT) is not required. Anti‑factor Xa assays may be useful in specific clinical situations, such as emergency surgery or life‑threatening bleeding.

Alternative Medications

• Rivaroxaban (Xarelto®): An oral direct factor Xa inhibitor dosed once daily for most indications. Similar efficacy for NVAF and VTE; associated with a higher risk of gastrointestinal bleeding compared with apixaban in some observational studies.
• Edoxaban (Savaysa®): An oral direct factor Xa inhibitor dosed once daily. Indicated for NVAF and VTE treatment; requires initial parenteral anticoagulation for at least 5 days before initiating for VTE.
• Dabigatran (Pradaxa®): An oral direct thrombin (factor IIa) inhibitor dosed twice daily. Indicated for NVAF and VTE treatment; requires initial parenteral anticoagulation for 5–10 days before initiating for VTE.
• Warfarin (Coumadin®): A vitamin K antagonist that has been the standard oral anticoagulant for decades. Requires regular INR monitoring and dietary consistency. Remains the preferred agent for patients with mechanical heart valves and for those with severe renal impairment or antiphospholipid syndrome.
• Low molecular weight heparins (e.g., enoxaparin, dalteparin) and fondaparinux: Injectable anticoagulants used for acute VTE treatment and prophylaxis; often used as bridging therapy when oral agents are interrupted.

Clinical Efficacy

In the pivotal phase 3 ARISTOTLE trial (18,201 patients with nonvalvular atrial fibrillation and at least one additional risk factor for stroke), apixaban 5 mg twice daily reduced the risk of stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year; p

Important:

Eliquis (apixaban) is a prescription anticoagulant that must be used under the supervision of a qualified healthcare provider. A comprehensive medical evaluation, including assessment of renal function, hepatic function, and bleeding risk, is required before initiating therapy. Do not stop taking Eliquis without consulting your prescribing physician, as premature discontinuation significantly increases the risk of stroke and other thromboembolic events. This medication increases the risk of serious and potentially fatal bleeding; seek immediate medical attention if you experience any signs of unusual bleeding, including blood in urine or stool, coughing up blood, vomiting material that looks like coffee grounds, or any bleeding that will not stop. Notify your healthcare provider immediately if you experience back pain, numbness or muscle weakness in your lower body, or loss of bladder or bowel control, which may indicate a spinal hematoma. Eliquis is not recommended for patients with prosthetic heart valves or triple‑positive antiphospholipid syndrome. Inform all healthcare professionals, including dentists, that you are taking Eliquis before any surgical or invasive procedure. Keep out of reach of children and never share your medication with others. An FDA‑approved reversal agent (andexanet alfa) is available for life‑threatening or uncontrolled bleeding; activated charcoal may be used in cases of overdose. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider.

How to buy Generic Eliquis no prescription U.S. Online Pharmacy